The genetic polymorphism I148M of patatin-like phospholipase domain-containing 3 (PNPLA3) is robustly associated with hepatic steatosis and its progression to steatohepatitis, fibrosis, and cancer. Hepatic stellate cells (HSCs) are key players in the development of liver fibrosis, but the role of PNPLA3 and its variant I148M in this process is poorly understood. Here we analyzed the expression of PNPLA3 during human HSC activation and thereby explored how a PNPLA3 variant impacts hepatic fibrogenesis. We show that expression of PNPLA3 gene and protein increases during the early phases of activation and remains elevated in fully activated HSCs (P < 0.01). Knockdown of PNPLA3 significantly decreases the profibrogenic protein alpha-smooth muscle actin (P < 0.05). Primary human I148M HSCs displayed significantly higher expression and release of proinflammatory cytokines, such as chemokine (C-C motif) ligand 5 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.001), thus contributing to migration of immune cells (P < 0.05). Primary I148M HSCs showed reduced retinol (P < 0.001) but higher lipid droplet content (P < 0.001). In line with this, LX-2 cells stably overexpressing I148M showed augmented proliferation and migration, lower retinol, and abolished retinoid X receptor/retinoid A receptor transcriptional activities but more lipid droplets. Knockdown of I148M PNPLA3 (P < 0.001) also reduces chemokine (C-C motif) ligand 5 and collagen1a1 expression (P < 0.05). Notably, I148M cells display reduced peroxisome proliferator-activated receptor gamma transcriptional activity, and this effect was attributed to increased c-Jun N-terminal kinase, thereby inhibiting peroxisome proliferator-activated receptor gamma through serine 84 phosphorylation and promoting activator protein 1 transcription. Conversely, the c-Jun N-terminal kinase inhibitor SP600125 and the peroxisome proliferator-activated receptor gamma agonist rosiglitazone decreased activator protein 1 promoter activity. Conclusions: These data indicate that PNPLA3 is required for HSC activation and that its genetic variant I148M potentiates the profibrogenic features of HSCs, providing a molecular mechanism for the higher risk of progression and severity of liver diseases conferred to patients carrying the I148M variant. (HEPATOLOGY 2017;65:1875-1890. P atatin-like phospholipase domain-containing 3 (PNPLA3), alternatively known as adiponutrin and calcium-independent phospholipase A2 epsilon, belongs to a novel group of lipid-metabolizing enzymes comprising the PNPLA family. Expression of PNPLA3 in human liver is 10-fold higher than in adipose tissue and shares its greatest homology with adipose triglyceride lipase (PNPLA2).
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(5) So far, knockout mouse models for PNPLA3 have shown no phenotype, I148M overexpression in hepatocytes or I148M knock-in resulted in hepatic steatosis development, and molecular mechanisms explaining the acceleration of liver inflammation and fibrosis observed in human clinical studies are still missing. (6) (7) (8) Liver fibrosis represents the consequence of a sustained healing response originating from chronic injury. It is characterized by excessive accumulation of extracellular matrix components and can eventually lead to cirrhosis. (9) Hepatic stellate cells (HSCs) are key players in extracellular matrix deposition and the dominant source of liver myofibroblasts across different types of liver injury. (10) Upon liver injury, quiescent HSCs undergo a phenotypic and metabolic switch, known as "activation," leading to the acquisition of a myofibroblast-like phenotype with loss of vitamin A. Likewise, HSC activation leads to the release of chemotactic factors and acquisition of specific receptors, thus allowing activated HSCs to closely interact with other hepatic cells. (11) Although expression of PNPLA3 in HSCs has been recently reported, (12) no information on its regulation during human HSC activation or the possible role of the I148M variant in fibrogenesis is currently available. Our results show that PNPLA3 is required for human HSC activation and that the I148M variant confers proinflammatory and profibrogenic properties to HSCs, leading to increased proliferation, migration, production, and release of cytokines and chemokines, thus boosting liver injury.
Materials and Methods

ISOLATION AND CULTURE OF PRIMARY HUMAN HSCs, LX-2 CELLS, AND THP-1 CELLS
HSCs were isolated from normal liver tissue from surgical resections unsuitable for transplantation, approved by the ethics committee of the Medical University of Florence, using a procedure described elsewhere. (13) HSCs were seeded on uncoated plastic dishes and cultivated with Iscove's modified medium (Dulbecco's medium; EuroClone, Italy) supplemented with 20% fetal bovine serum, 1% glutamine 200 mM, sodium pyruvate 100 mM, nonessential amino acid solution 1003, and antibiotic antimycotic solution 1003 (Gibco Life Technologies, Carlsbad, CA). Primary HSCs between passages 1 and 8 were used for this study. Primary HSCs at the same passage were used for comparison experiments of wild-type (WT) and I148M PNPLA3. The genotype of each isolated HSC line was analyzed by real-time PCR for the I148M single-nucleotide polymorphism, as done routinely in our clinical research center. Homozygote genotypes were used in this study (C/C as WT and G/G as I148M).
LX-2 cells, an immortalized HSC line, (14) were kindly provided by Prof. S.L. Friedman (Mount Sinai School of Medicine, New York, NY) and cultured with Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 5% non-heatinactivated fetal bovine serum and 1% penicillin/ streptomycin solution (EuroClone). The genotype of LX-2 cells was analyzed by real-time PCR for the I148M single-nucleotide polymorphism, as mentioned above.
THP-1 cells, a human monocyte leukemia cell line (LGC-Standards, Wesel, Germany), were maintained
in culture with Roswell Park Memorial Institute medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin solution; in order to obtain a macrophage-like phenotype, THP-1 cells were incubated for 3 days with phorbol 12-myristate 13-acetate (Sigma-Aldrich, St. Louis, MO) at 100 ng/mL.
STABLE PNPLA3 WT AND I148M STABLE TRANSFECTION
LX-2 cells were transfected with 15 ng of pcDNA3.1/V5-His-TOPO (Thermo Fisher Scientific, Carlsbad, CA) carrying either the PNPLA3 WT or the I148M sequence, cloned between T7 promoter and the bovine growth hormone terminator sequences, using Amaxa Nucleofector Technology (U-25 program; Lonza). Clones were selected using 500 ng/mL of geneticin (G418; Sigma-Aldrich) and subjected to V5-tag western blotting and real-time PCR analysis.
MIGRATION ASSAY
Cell migration was measured in modified Boyden chambers, as described. (13) Cells were fixed in methanol and stained with hematoxylin/eosin solution before counting. 
PNPLA3 SILENCING
REAL-TIME PCR ANALYSIS
RNA was isolated from primary HSCs and LX-2 by NucleoSpin RNA (Macherey-Nagel GmbH & Co., Germany) according to the manufacturer's instructions. One microgram of RNA was reverse-transcribed using Moloney murine leukemia virus enzyme, 103 buffer, for complementary DNA synthesis and Deoxynucleotide Mix (10 mM; Sigma-Aldrich). Two microliters of diluted complementary DNA were loaded together with SYBR Select Master Mix on a 96-well plate to perform real-time PCR analysis (Applied Biosystem, Thermo Fisher Scientific). Forward and reverse primers for each gene of interest were specifically designed and used at 10 pmol/lL (Eurofins Genomics, Germany).
WESTERN BLOT ANALYSIS
Whole-cell extracts were obtained using radio immunoprecipitation assay buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM trishydroxymethylaminomethane, pH 8.0) containing complete ethylene diamine tetraacetic acid-free protease inhibitor cocktail tablets (Roche Diagnostics GmbH, Germany) and phosphatase inhibitors (20 mM bglycerophosphate, 10 mM 4-nitrophenylphosphate, 50 mM sodium vanadate; Sigma-Aldrich). Primary antibodies were diluted in 3% bovine serum albumin, trishydroxymethylaminomethane-buffered salineTween 13 solution at different concentrations: rabbit polyclonal to PNPLA3 (1:1,000; Abcam, Cambridge, UK), rabbit polyclonal to phosphostress-activated protein kinase/c-Jun N-terminal kinase (JNK) (Thr183/Tyr185), total stressactivated protein kinase/JNK (1:1,000; all from Cell Signaling, Danvers, MA), monoclonal antiactin, a-smooth muscle (1:3,000; Sigma-Aldrich), and rabbit polyclonal to calnexin and b-actin (1:10,000; Sigma-Aldrich). Proteins were detected by enhanced chemiluminescence (GE Amersham, Arlington Heights, IL).
FLOW CYTOMETRY
Primary human HSCs were detached and incubated with a freshly prepared working solution of 1 lg/mL BODIPY 493/503 (Thermo Fisher Scientific) in phosphate-buffered saline for 30 minutes at 378C. Thereafter, 5 lg/mL of propidium iodide (Sigma-Aldrich) was added to each tube for 5 minutes before flow cytometric analysis. Green fluorescence (525 nm) of BODIPY was used to measure the intracellular lipid droplet (LD) formation, as described. (15) Retinol contained in primary HSCs was measured by exploiting its intrinsic autofluorescence. Approximately 6 3 10 4 cells were suspended in phosphate-buffered saline, excited with a 351-nm laser, and analyzed with flow cytometry. Flow cytometry was performed with BD FACSCanto II and BD FACSDiva software (Becton Dickinson).
GAS CHROMATOGRAPHY-NEGATIVE ION CHEMICAL IONIZATION-MASS SPECTROMETRY OF FREE FATTY ACIDS
Primary human HSCs were disrupted in 5 mL of methyl-tert-butylether and 1.5 mL of methanol. Each sample was immediately spiked with 4 nM of fatty acid (FA) 15:0 as internal standard. Then, lipids were extracted as described. (16) Lipid extracts were dried and dissolved in 100 lL of a pentafluorobenzyl bromide solution (5% in acetonitrile) and 20 lL of N,N-diisopropyl ethanolamine. After 10 minutes of incubation at room temperature, samples were evaporated under a stream of nitrogen and suspended in 70 lL of hexane. A 7890B/5977A MSD gas chromatographmass spectrometer (Agilent, Santa Clara, CA) equipped with a TR-FAME 30-m column was used in split mode with 1 mL/minute helium as carrier gas and a 2508C injector temperature. The initial oven temperature of 1508C was held for 1 minute, then increased to 2508C at a rate of 108C/minute and held for 5 minutes. The mass spectrometer was run in negative ion chemical ionization radiofrequency mode. Fatty acids were detected in full scan as carboxylates after loss of the pentafluorobenzyl moiety. Methane was used as CI gas. Source temperature was set to 1508C and the transfer line temperature to 2508C. Quantitation of FAs was performed by correlating integrated areas of FAs versus the integrated area of FA 15:0.
ELECTROPHORETIC MOBILITY SHIFT ASSAY
Nuclear extracts from LX-2 overexpressing PNPLA3 WT and I148M were obtained after lysis with 0.2% Nonidet P40 and specific cytosolic buffer (10 mM 4-[2-hydroxyethyl]-1-piperazine ethanesulfonic acid [pH 7.5], 3 mM MgCl 2 , 14 mM KCl, 5% glycerol, and 1 mM dithiothreitol) containing protease inhibitors (40 mg/mL bestatin, 0.5 mM pefabloc, 700 ng/mL pepstatin A, 2 mg/mL aprotinin, and 0.5 mg/mL leupeptin; all from Roche, Indianapolis, IN). After centrifugation, the supernatants were dissolved with the nuclear buffer (10 mM 4-[2-hydroxyethyl]-1-piperazine ethanesulfonic acid [pH 7.5], 3 mM MgCl 2 , 400 mM NaCl, 5% glycerol, and 1 mM dithiothreitol; Sigma-Aldrich) containing a protease inhibitor cocktail. Double-stranded peroxisome proliferator-activated receptor gamma (PPARc; 100 ng) response elements were labeled with P 32 adenosine triphosphate, purified using the QIAquick Nucleotide Removal kit (Qiagen, Germany), and incubated with a binding buffer (10 mM trishydroxymethylaminomethane [pH 8.0], 40 mM KCl, 0.05% Nonidet P40, 6% glycerol). Four micrograms of either cytosolic or nuclear extract were incubated with labeled probes and buffer for 10 minutes at room temperature and loaded on 4% acrylamide/bis-acrylamide gel (20 lL). After the run, gel was dried for 1 hour at 608C and transferred into a developing cassette (Biomax; Kodak) for overnight film exposure at -808C.
LUCIFERASE ASSAY
WT or I148M stably overexpressing LX-2 cells were seeded in a 24-well plate and transiently transfected with 0.3 lg/well of an activator protein 1 (AP-1) or DR1 peroxisome proliferator response elementluciferase construct using Fugene transfection reagent (Promega, Madison, WI) in sterile OptiMeM for 12 hours. Complete medium was then replaced for an additional 24 hours, and the cells were lysed using a tampon solution (4% Triton X-100, glycyl-glycine 100 mM, MgSO 4 100 mM, ethylene glycol tetraacetic acid 250 mM) for 1 hour at room temperature on a shaker platform. Extracts were then combined with the solution containing the substrate (luciferin 2.5 mM and adenosine triphosphate 20 mM; Sigma-Aldrich) and analyzed with a luminometer (Lumat LB9507; EG&G Berthold, Germany). Plasmid control DNA-JNK-WT and plasmid control DNA3-JNK-dominant negative were a gift of Dr. C. Glineur (Pasteur Institute, Lille, France); AP-1-luciferase was bought from Takara Bio; the TK-DR5-luc was a gift from Dr. David Mangelsdorf (University of Texas Southwestern Medical Center, Dallas, TX); 4XDR2-EPOTK-luc was a gift from Dr. Henry M. Sucov (CIRM Center for Regenerative Medicine and Stem Cell Research at the University of Southern California, Los Angeles, CA); pSG5-PPARg was a gift of Dr. Johan Auwerx (EPFL, Lausanne, Switzerland).
CYTOKINE PROFILING
Media from LX-2 stable overexpressing WT and I148M was collected after 3 days of culture, immediately centrifuged at 11 3 10 Systems, Minneapolis, MN), according to the manufacturer's instructions.
STATISTICAL ANALYSIS
Unless otherwise indicated, data presented as bar graphs are the mean 6 standard deviation of three independent experiments with at least two replicates. Statistical analysis was performed by the Student t test. P < 0.05 was considered significant.
Results
PNPLA3 EXPRESSION IS INDUCED DURING ACTIVATION OF HSCs AND REQUIRED FOR ACTIVATED MYOFIBROBLAST-LIKE PHENOTYPE
We first evaluated changes in PNPLA3 expression in the early phases of trans-differentiation of freshly isolated human HSCs on uncoated plastic dishes by western blotting. Notably, from 3 to 7 days after isolation, we detected a significant 2-fold increase in PNPLA3 expression (P < 0.001), which paralleled the induction of the activation marker alpha-smooth muscle actin (a-SMA) (Fig. 1A) , and reached a maximum of 3.7-fold after 15 days (P < 0.01), a time point where cells are considered fully activated. We also found that PNPLA3 mRNA continuously increases from the first to the fourth passage (P < 0.01) and again follows the pattern of the profibrogenic marker procollagen1a1 (P < 0.05) (Fig. 1B) . Previous studies reported (2) that PNPLA3 expression is extremely variable among human tissues and that the highest amount was found in liver. In addition and supporting previous findings, (12) we aimed to evaluate its expression in comparison to other lipases and in different cell types. Our analysis revealed that PNPLA3 is the major lipase in activated HSCs with a 2-fold higher level than in primary human hepatocytes (Fig. 1C) , while adipose triglyceride lipase was expressed at higher levels in hepatocytes. In line with our in vitro findings, immunofluorescence staining revealed colocalization of PNPLA3 and a-SMA in human nonalcoholic steatohepatitis (NASH) liver, while staining was absent in normal liver (Supporting Fig. S1 ). To further evaluate whether PNPLA3 is essential for activated HSCs, we analyzed the impact of gene silencing. PNPLA3-targeting siRNA significantly decreased endogenous protein levels, with a reduction of approximately 70%, compared to cells transfected with nontargeting siRNA (Fig. 1D) . Notably, knockdown of PNPLA3 (P < 0.01) was associated with a significant reduction of the profibrogenic marker a-SMA by 40% (P < 0.05), demonstrating that PNPLA3 is positively associated with HSC activation. Collectively, our data indicate that PNPLA3 is induced during activation of human HSCs and its expression is required for an active/ profibrogenic myofibroblast-like phenotype.
THE I148M PNPLA3 CONFERS A PROINFLAMMATORY PHENOTYPE TO PRIMARY HUMAN HSCs
We next compared the properties of HSCs isolated from patients carrying either WT (n 5 3) or the I148M (n 5 3) PNPLA3. Notably, we found significantly enhanced expression of two key cytokines, chemokine (C-C motif) ligand 5 (CCL5) (P < 0.01) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (P < 0.001), along with the induction of chemokine (C-X-C motif) ligand 8 (CXCL8) (P 5 0.1) and transforming growth factor-b (P 5 0.07) ( Fig. 2A) . Remarkably, these were untreated cells, thus suggesting a mechanistic connection between I148M and an inflammatory phenotype of HSCs. To test this hypothesis, we exposed THP-1 differentiated macrophages to culture medium collected from primary HSCs, expressing either the WT or the I148M allele. Migration assays showed enhanced macrophage chemotaxis toward medium collected from primary I148M expressing HSCs (Fig. 2B) . Notably, we measured significantly increased levels of LD in untreated primary HSCs carrying the PNPLA3 variant compared to WT carrier HSCs (P < 0.001), as shown by BODIPY staining (Fig. 2C, Supporting  Fig. 3B ). Interestingly, expression of PPARc1, a key regulator of lipid homeostasis and HSC quiescence, (17) was significantly reduced (P < 0.001) in untreated primary I148M HSCs (Fig. 2D ) compared to WT PNPLA3 HSCs. Taken together, the presence of the I148M isoform reduces PPARc1 expression, despite accumulation of LDs, and induces proinflammatory features to HSCs, thus promoting immune cell chemotaxis at the site of liver injury.
FIG. 1.
PNPLA3 is required for activation of primary human HSCs. PNPLA3 increases during trans-differentiation of primary human HSCs. (A) Total protein was extracted from freshly isolated human HSCs (WT PNPLA3) after 3, 7, and 15 days of culture and analyzed by western blotting. Representative blots are displayed and refer to three independent HSC isolations. Densitometric analysis was performed using ImageJ software, and data are normalized to calnexin. *P < 0.05, **P < 0.01, ***P < 0.001 versus day 3; # P < 0.05 versus day 7. (B) PNPLA3, collagen1a1, and PPARc expression in primary HSCs at different passages, measured by real-time PCR and normalized to 18s as internal control. *P < 0.05, **P < 0.01 versus passage 1. (C) PNPLA3 is highly expressed in HSCs compared to hepatocytes and to other lipases. mRNA was isolated from fully activated human primary HSCs and human hepatocytes and quantified by real-time PCR. (D) PNPLA3 knockdown decreases the amount of the profibrogenic marker a-SMA. Total protein from primary HSCs transfected with nontargeting siRNA or with siRNA targeting PNPLA3 was analyzed by western blotting. Data shown are representative of three independent siRNA transfections. *P < 0.05, **P < 0.01 versus small interfering control. Abbreviations: ATGL, adipose triglyceride lipase; HSL, hormone-sensitive lipase; MGL, monoacylglycerol lipase; si, small interfering.
FIG. 2.
Comparison between primary human WT and I148M PNPLA3 HSCs shows that the variant carriers express and release proinflammatory mediators that stimulate macrophage migration. (A) Expression of CCL5, GM-CSF, CXCL8, transforming growth factor-b and (D) PPARc1 was measured by real-time PCR in primary human untreated I148M (n 5 3) and WT (n 5 3) HSCs. Data are normalized to 18s. **P < 0.01, ***P < 0.001 versus WT carriers. (B) Differentiated THP-1 macrophages were exposed for 7 hours to culture medium collected from primary HSCs, and migration rate was measured, as described in Materials and Methods. *P < 0.05 versus WT HSC culture medium. (C,D) Primary HSCs carrying I148M express significantly low PPARc1 but show higher LD content compared to WT PNPLA3 HSCs. BODIPY staining (C) and mRNA (D) were analyzed by real-time PCR and flow cytometry, respectively, in untreated primary human HSCs carrying either the WT or the I148M PNPLA3. Data are presented as normalized expression with 18s for PPARc and mean fluorescence intensity for BODIPY. Data are representative of three independent experiments, using at least duplicates. ***P < 0.001 versus WT carriers. Abbreviation: TGF, transforming growth factor.
STABLE OVEREXPRESSION OF THE I148M VARIANT IN LX-2 CELLS CONFERS THE PROINFLAMMATORY PHENO-TYPE OBSERVED IN PRIMARY HUMAN HSCs
Based on our findings in primary human HSCs, we next further explored the functional impact of I148M PNPLA3 by stable overexpression in the immortalized human HSC line LX-2. (14) We selected stable clones expressing similar amounts of V5-tag PNPLA3 at the RNA (Fig. 3A) and protein (Fig. 3B ) levels. As shown previously on primary human HSCs, I148M overexpressing LX-2 clones had significantly higher mRNA levels of CCL5, CCL2, GM-CSF (P < 0.001), and CXCL8 (P < 0.01) (Fig. 3C) . To test whether the release of cytokines from cells overexpressing the PNPLA3 variant was able to effectively promote monocyte/macrophage chemotaxis, we used conditioned medium from untreated LX-2 overexpressing either the WT or the I148M PNPLA3 in migration assays. Medium collected from I148M overexpressing LX-2 significantly induced greater chemotaxis of both monocytes (P < 0.01) and differentiated THP-1 macrophages (P < 0.05) (Fig. 3D) . To further characterize the medium composition, we performed a cytokine array analysis ( Fig. 3E; Supporting Fig. S2 ), which confirmed higher secretion of CCL5, CCL2, CXCL8, GM-CSF, and CXCL1 (P < 0.001) from I148M carrying cells. In summary and consistent with our prior findings in primary HSCs, stable overexpression of I148M PNPLA3 in LX-2 promotes the release of proinflammatory mediators that favor immune cell recruitment.
THE I148M VARIANT AUGMENTS PROLIFERATION AND CHEMOTAXIS OF OVEREXPRESSING LX-2, AND ITS DOWN-REGULATION DECREASES FIBROGENIC GENE EXPRESSION
Notably, transient knockdown of the I148M PNPLA3 variant (P < 0.001) lowered the expression of profibrogenic genes, such as CCL5 and procollagen1a1 (P < 0.05) (Fig. 4A ). Proliferation and chemotaxis are key properties acquired by activated HSCs. (9) We detected a significantly increased proliferation rate (Fig. 4B) and chemotaxis (Fig. 4C ) of untreated I148M overexpressing LX-2 compared to WT cells, along with higher expression of cyclins D1 and D2, two key genes involved in cell cycle progression (Fig. 4B) . Of note, as reported in primary cells, LX-2 overexpressing the PNPLA3 variant have significantly increased neutral lipids (P < 0.05) (Fig. 4D) . Taken together, these findings indicate that the PNPLA3 variant impacts key features of activated HSCs, providing additional evidence for its role in mediating fibrogenesis.
TOTAL RETINOL CONTENT AND RETINOID X RECEPTOR/RETINOIC ACID RECEPTOR SIGNALING ARE IMPAIRED IN HSCs EXPRESSING THE PNPLA3 VARIANT
Based on a report (12) indicating a potential role of PNPLA3 as retinyl palmitate lipase in HSCs, we measured by flow cytometry the total content of retinol in both primary HSCs and overexpressing LX-2 cells. Interestingly, we detected significantly lower (P < 0.001) retinol content in untreated primary HSCs expressing the I148M variant compared to WT PNPLA3 HSCs (Fig. 5A, Supporting Fig. S3 ). These observations were supported by the measurements obtained in LX-2, where the overexpressing I148M cells display significantly lower retinol amount (P < 0.05) in comparison to cells overexpressing the WT isoform (Fig. 5B) . Data have shown the capability of retinoic acids (all-trans and 9-cis retinoic acid) to activate retinoid X receptor (RXR) and retinoic acid receptor (RAR) signaling, resulting in down-regulation of profibrogenic features in HSCs. (18) Therefore, we assessed whether retinoic acid receptor pathways were affected by the PNPLA3 variant, using luciferase reporter activity of the DR2 and DR5 response elements. (19, 20) Baseline DR2 and DR5 activation was reduced in PNPLA3 I148M LX-2 overexpressing cells (Fig. 5C ), whereas cotransfection with RARa increased the activity of both DR2 and DR5 luciferase in LX-2 overexpressing the WT PNPLA3. RARa cotransfection in LX-2 overexpressing the PNPLA3 variant did not increase either the DR2 or the DR5 luciferase activity, thus demonstrating a lack of retinoids activating the nuclear receptors RXR/RAR (Fig.  5C) . Collectively, our data clearly display that HSCs carrying I148M PNPLA3 retain less retinol content, resulting in abolished RXR/RAR transcriptional activity through the specific DR2 and DR5 response elements.
FIG. 3.
I148M stable overexpressing LX-2 cells express and release high levels of CCL5, CCL2, GM-CSF, and CXCL8, promoting monocyte/macrophage migration. (A) Selection of LX-2 clones stably overexpressing either WT or I148M variant (n 5 3 each genotype). PNPLA3 expression was analyzed by real-time PCR and normalized to 18s. (B) V5-tag PNPLA3 was analyzed by western blotting, and representative blots are displayed. Densitometric analysis was performed using ImageJ, and data are normalized to calnexin. (C) Cytokine expression in untreated cells was analyzed by real-time PCR and normalized to 18s. **P < 0.01, ***P < 0.001 versus WT LX-2. (D) Migration rate of undifferentiated THP-1 cells (left panel) or differentiated macrophages (right panel) was measured after 7-hour exposure to medium collected from WT or I148M overexpressing LX-2. *P < 0.05, **P < 0.01 versus WT medium. (E) Proinflammatory cytokines are released from LX-2 overexpressing the variant. The cytokine array quantification plot is displayed. Culture medium was collected from untreated WT and I148M overexpressing LX-2. Densitometric analysis was performed using ImageJ software, and data are normalized to positive control dots. Data are representative of three independent experiments, using at least duplicates *P < 0.05, **P < 0.01, ***P < 0.001 versus WT medium. Abbreviations: EV, empty vector; IL-6, interleukin-6; MIF, migration inhibitory factor; PAI-1, plasminogen activator inhibitor 1. Expression of cyclins D1 and D2 was quantified by real-time PCR and normalized to 18s. (C) Migration rate was analyzed in stable overexpressing LX-2 exposed to culture medium for 5 hours. (D) LX-2 overexpressing I148M display higher numbers of LDs compared to WT carriers. BODIPY staining was measured by flow cytometry in untreated LX-2 overexpressing either WT or I148M PNPLA3. Data are presented as mean fluorescence intensity. Data are representative of three independent experiments, using at least duplicates. *P < 0.05, ***P < 0.001 versus small interfering control; *P < 0.05, **P < 0.01, ***P < 0.001 versus WT carriers. Abbreviations: MFI, mean fluorescence intensity; si, small interfering.
DIFFERENCES IN AMOUNTS OF MONOUNSATURATED FAs AND POLYUNSATURATED FAs BETWEEN PRIMARY HUMAN HSCs CARRYING THE WT OR THE I148M PNPLA3
Based on recent reports highlighting the discrepancies among FA compositions in human carrying the WT or the I148M PNPLA3, we investigated whether this difference might influence the profibrogenic phenotype observed in our study. Our analysis revealed a significant increase in two monounsaturated FAs, oleic and vaccenic acids (Table 1) , supporting previous findings about the enhanced stability of PNPLA3 protein particularly due to oleic acid. Moreover, we observed that different concentrations of oleic acid are able to induce PNPLA3 and a-SMA increases at the protein level (Supporting Fig. S4A ) and cell migration (Supporting Fig. S4B ) in I148M expressing LX-2 cells. In addition, we observed augmented polyunsaturated FAs, in particular those of the n-6 series such as linoleic and arachidonic acids ( Table 1) . As Total retinol content was measured by flow cytometry. Data are presented as mean fluorescence intensity and are representative of three independent experiments, using three different HSC lines (n 5 3 each genotype). ***P < 0.001 versus WT carriers. (C) Activity of RXR and RAR response elements DR2 and DR5 is abolished in LX-2 overexpressing the I148M PNPLA3 compared to WT carriers. Luciferase activity (%) was measured in overexpressing cells after 48 hours of transfection with or without the specific ligands. ***P < 0.001 versus WT carriers. Abbreviation: MFI, mean fluorescence intensity.
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result, the ratio between monounsaturated and saturated FAs was significantly increased (Supporting Table S1 ). Taken together, our observations indicate that the I148M allele influences the FA profile in HSCs, thus influencing the fibrogenic activity of HSCs.
ENHANCED AP-1 AND REDUCED PPARc BINDING ACTIVITIES CONTRIBUTE TO THE PROINFLAMMATORY AND PROFIBROGENIC PROPERTIES OF THE I148M ALLELE IN HSCs
To further uncover the molecular mechanism(s) behind the proinflammatory and profibrogenic features of the I148M allele in HSCs, we focused on the free FA profile as PNPLA3 may play a major role in lipid partitioning and signaling. (2, 21) Comparison between the two PNPLA3 isoforms in primary human HSCs revealed a significant increase in oleic acid in HSCs carrying the variant (Table 1) . Moreover, we found increased levels of polyunsaturated free FAs, such as linoleic (18:2) and linolenic (18:3) acids, in primary I148M HSCs (Table 1) . These FAs are known to act as endogenous ligands of PPARc, a pivotal regulator of lipid homeostasis and inflammation (22) and important for maintaining HSC quiescence. (17) Because PPARc1 expression in primary HSCs carrying the I148M variant was significantly reduced (Fig. 2D) , we investigated whether PPARc activity might be modulated by phosphorylation at specific inhibitory residues, despite the presence of FA as endogenous ligands. Interestingly, we detected significant PPARc phosphorylation at serine 84 (P < 0.05) in I148M expressing cells (Fig. 6A) , resulting in reduced PPARc binding and lower promoter PPAR/DR1-luciferase activity (Fig. 6B) .
Inhibition at serine 84 is mediated by JNK phosphorylation. (23) Notably, in I148M overexpressing LX-2 phospho-JNK increased drastically (Fig. 6C) . Because JNK plays a role in activating the transcription factor AP-1 and PPARc can directly interfere with the AP-1 signaling pathway by interacting with JunD, (17) we determined the activity of AP-1 using an AP-1 luciferase construct. I148M overexpressing cells displayed a 2-fold induction of AP-1-dependent luciferase activity (Fig. 6D) , while the PPARc agonist rosiglitazone reduced luciferase activity, indicating that reduced PPARc activity in activated HSCs may account for the abnormally high AP-1 activity in I148M carrying cells (Fig. 6D) . To further establish the role of JNK in AP-1 transcriptional activity, I148M cells were either transfected with dominant negative JNK or treated with the specific JNK inhibitor SP600125. In both cases we detected a decrease in AP-1 luciferase activity, which was significant with the inhibitor (Fig. 6D ). These observations indicate that PNPLA3 I148M expressing cells show higher numbers of specific FA species and enhanced phosphorylation of JNK, resulting in PPARc inhibition and increase of AP-1 transcriptional activity, characterizing the augmented profibrogenic features of HSCs.
Discussion
In this study we show that the presence of PNPLA3 I148 directly confers a more inflammatory and fibrogenic phenotype to human HSCs, through mechanisms that favor increased risk for developing fibrosis and further progression of liver disease. Over the past years, several groups have demonstrated that the influence of the I148M variant was linked not only to hepatic fat accumulation but also to progression of steatohepatitis, fibrosis, and cancer on an alcoholic or nonalcoholic background compared to subjects , and I148M nuclear with PPARc antibody (lane 6). DR1 luciferase activity (%) was measured in overexpressing LX-2 after 48-hour transfection. **P < 0.01 versus WT carriers. (C) The JNK pathway is up-regulated in I148M LX-2. Phosphorylated and total JNK were analyzed by western blotting. Representative blots are displayed, densitometric analysis was performed using ImageJ software, and data are normalized to calnexin. *P < 0.05 versus WT carriers. (D) AP-1 luciferase activity (%) is increased in I148M cells and can be counteracted by rosiglitazone and the JNK-specific inhibitor SP600125. AP-1 luciferase activity was measured in overexpressing LX-2 after 48-hour transfection with or without rosiglitazone and SP600125. *P < 0.05, **P < 0.01 versus WT carriers. Abbreviations: DN, dominant negative; p-, phosphorylated.
carrying the WT isoform. (3) (4) (5) 24) Moreover, mice lacking PNPLA3 displayed no significant phenotypic differences compared to WT animals, (8) while overexpression of the I148M variant in hepatocytes resulted in liver steatosis. (6) We report herein that PNPLA3 is induced at the early phases of HSC transdifferentiation and is remarkably maintained once achieving the fully activated phenotype. Moreover, PNPLA3 enhancement is in line with other profibrogenic key factors, such as a-SMA and collagen1a1, which were conversely down-regulated after PNPLA3 transient knockdown, suggesting a direct role of PNPLA3 for HSC activation.
A key relevant finding of this study is that the marked production and release of proinflammatory cytokines, such as CCL5 and GM-CSF, from primary HSCs expressing the variant caused enhanced macrophage and monocyte migration, thus providing a mechanism by which I148M may favor steatohepatitis and its progression toward fibrosis. In this context, the possible contribution of PNPLA3 variants in other hepatic cells, such as Kupffer cells, needs to be explored in future studies.
The generation of stable overexpressing cells represented an efficient tool for studying the molecular implications and consequences of the I148M isoform in HSCs. Consistent with our findings in primary HSCs, the variant conferred also to LX-2 a proinflammatory phenotype, leading to excess release of cytokines and chemokines, which in turn stimulated immune cell chemotaxis. (25, 26) Moreover, cells overexpressing the variant showed increased proliferation, associated with increased expression of cyclins D1/D2, which could alter cell cycle regulation leading to fibrosis and, eventually, cancer. (27) In addition to proinflammatory mediators production, primary human HSCs carrying the I148M display less retinol content than primary WT HSCs. This latter finding was also supported by LX-2 overexpressing the PNPLA3 variant, when compared with WT carriers. Moreover, the luciferase activity of the retinoic acid response elements DR2 and DR5 clearly highlighted the profound difference between WT and I148M HSCs in terms of retinol homeostasis and intracellular signaling. Of note, the loss of retinoid content has been so far considered a hallmark for transition of HSCs from quiescence to a myofibroblast-like phenotype, whereas RXR and RAR agonists exert antifibrotic activities in HSCs. (28) We also detected more LD compared to primary WT PNPLA3 HSCs, and LX-2 cells overexpressing the variant replicated this finding. This might represent a mechanistic link with data reported by Pirazzi et al., (12) where the I148M carrying HSCs resulted in loss of the lipase activity of the native WT PNPLA3. We further investigated PPARc transcription and signaling as this transcription factor has been linked to the lipogenic quiescent phenotype of HSCs. (17) As supposed, the lower expression of PPARc in primary I148M HSCs was accompanied by reduced transcriptional and binding activity in stable overexpressing cells. Notably, impaired PPARc function was due to phosphorylation at its inhibitory residue, serine 84. JNK can regulate PPARc activity, (29) is up-regulated in patients with NASH, and is involved in HSC activation and fibrogenesis, (30) promoting a-SMA expression as well as proliferation and migration. (31) Moreover, JNK positively phosphorylates JunD in HSCs, thus promoting AP-1 transcriptional activity, while JunD binding on AP-1 promoter is inhibited by PPARc. (32) Remarkably, AP-1 positively contributes to the release of proinflammatory cytokines from HSCs, including CCL5, (25) CXCL8, and CCL2. (33) Therefore, increased AP-1 transcriptional activity in I148M overexpressing cells is supported by enhanced phosphorylation of JNK, while JNK inhibition results in AP-1 reduction. Moreover, rosiglitazone, a synthetic agonist of PPARc, lowers AP-1, suggesting that increased PPARc signaling might decrease the profibrogenic features of HSCs expressing the variant, through JNK inhibition.
Because PNPLA3 may play a major role in lipid partitioning and signaling, (2, 21) we explored its impact on free FA profiles in HSCs. The PNPLA3 variant was also associated with significantly increased abundance of oleic and vaccenic acids in primary I148M cells. These changes possibly contribute to enhance HSC activity, as shown by oleic acid-stimulated up-regulation of PNPLA3 and a-SMA expression and chemotaxis. We also detected higher amounts of polyunsaturated FAs in cells carrying the variant, in line with recent findings in human liver biopsies. (34) Along with recent reports, (35) a high amount of arachidonic acid, which contributes to the synthesis of proinflammatory metabolites, and JNK activation by lipotoxic FAs have been linked to hepatic lipid accumulation and peroxidation, inflammation, hepatocyte apoptosis, (36) and up-regulation of proinflammatory pathways such as AP-1 and nuclear factor jB (37) and thereby repression of PPARc. (17) Collectively, our data provide robust evidence that PNPLA3 I148M acts as a positive modulator of activated human HSCs, affecting secretion of proinflammatory cytokines, proliferation, and migration. Further in vivo studies are needed to validate the clinical relevance of our results to human nonalcoholic fatty liver disease, including more extensive immunohistochemical studies of PNPLA3 as well as unbiased liver tissue transcriptomic assessment of patients with biopsyproven NASH. While PPARc binding and transcriptional activity were diminished in I148M cells, JNK and AP-1 were up-regulated, thus contributing to the further characterization of the HSC phenotype. In vivo studies are required to verify our findings and to establish whether anti-inflammatory strategies, such as vitamin E supplementation, JNK inhibition, and/or PPARc/PPARc agonists, may represent a therapeutic strategy for patients carrying the I148M allele in the prevention of hepatic fibrosis and its progression toward cirrhosis and cancer.
